THE EMERGENCE OF ISONIAZID-RESISTANT CULTURES IN PATIENTS WITH PULMONARY TUBERCULOSIS DURING TREATMENT WITH ISONIAZID ALONE OR ISONIAZID PLUS PAS
- PMID: 14253244
- PMCID: PMC2555166
THE EMERGENCE OF ISONIAZID-RESISTANT CULTURES IN PATIENTS WITH PULMONARY TUBERCULOSIS DURING TREATMENT WITH ISONIAZID ALONE OR ISONIAZID PLUS PAS
Abstract
Previous reports from the Tuberculosis Chemotherapy Centre, Madras, have described a comparison of four regimens (three of isoniazid alone and one of isoniazid plus PAS) in the treatment of pulmonary tuberculosis and an investigation of the serum isoniazid levels in the patients concerned. The present report studies the emergence of isoniazid-resistant organisms in these patients during treatment. All patients with an unsatisfactory response to treatment yielded resistant cultures, showing that the isoniazid dosage was never too low to inhibit sensitive organisms. From the degree of resistance of the first resistant cultures and of the six-month cultures from the patients treated with isoniazid alone it was concluded that resistance emerged in two stages. In the first stage, very earlyin treatment, highly resistant mutant bacilli grew freely whatever the isoniazid dosage, but mutants of lower resistance were prevented from growing to an extent dependent on the peak isoniazid concentration in the serum. Consequently, when the isoniazid dosage was increased the proportion of patients with resistant organisms decreased, since fewer low-resistance strains were able to develop. In the second stage, organisms with relatively low resistance continued to multiply, though still partially inhibited by isoniazid, and became more resistant, particularly in slow inactivators. The first-stage events determined the results of treatment since, once resistance had emerged, its extent was unrelated to the patient's eventual progress. These findings emphasize the importance of early intensive chemotherapy and adjustment of the isoniazid dosage according to peak serum concentrations rather than concentrations measured three or six hours after the dose. Concomitant administration of PAS prevented emergence of isoniazid resistance in many patients and in others delayed its emergence and reduced its degree, possibly because growth in the second stage was slow.
Similar articles
-
A CONTROLLED COMPARISON OF STREPTOMYCIN PLUS PYRAZINAMIDE AND STREPTOMYCIN PLUS PAS IN THE RETREATMENT OF PATIENTS EXCRETING ISONIAZID-RESISTANT ORGANISMS.Tubercle. 1964 Jun;45:144-59. doi: 10.1016/s0041-3879(64)80072-6. Tubercle. 1964. PMID: 14161913 No abstract available.
-
The course of pulmonary tuberculosis in patients excreting organisms which have acquired resistance. Response to continued treatment for a second year with isoniazid alone or with isoniazid plus PAS.Bull World Health Organ. 1962;26(1):1-18. Bull World Health Organ. 1962. PMID: 14490064 Free PMC article.
-
Rate of inactivation of isoniazid in South Indian patients with pulmonary tuberculosis. 3. Serum concentrations of isoniazid produced by three regimens of isoniazid alone and one of isoniazid plus PAS.Bull World Health Organ. 1961;25(6):793-806. Bull World Health Organ. 1961. PMID: 13896635 Free PMC article.
-
CHEMOTHERAPY FOR PATIENTS WITH CULTURES RESISTANT TO STREPTOMYCIN, ISONIAZID AND PAS.Tubercle. 1963 Dec;44:443-5. Tubercle. 1963. PMID: 14101324 No abstract available.
-
The pharmacokinetics of para-aminosalicylic acid and its relationship to efficacy and intolerance.Br J Clin Pharmacol. 2020 Nov;86(11):2123-2132. doi: 10.1111/bcp.14395. Epub 2020 Jun 21. Br J Clin Pharmacol. 2020. PMID: 32470182 Free PMC article. Review.
Cited by
-
Negligible risk of inducing resistance in Mycobacterium tuberculosis with single-dose rifampicin as post-exposure prophylaxis for leprosy.Infect Dis Poverty. 2016 Jun 8;5(1):46. doi: 10.1186/s40249-016-0140-y. Infect Dis Poverty. 2016. PMID: 27268059 Free PMC article. Review.
-
The combination of meropenem and levofloxacin is synergistic with respect to both Pseudomonas aeruginosa kill rate and resistance suppression.Antimicrob Agents Chemother. 2010 Jun;54(6):2646-54. doi: 10.1128/AAC.00065-10. Epub 2010 Apr 5. Antimicrob Agents Chemother. 2010. PMID: 20368395 Free PMC article.
-
Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 2.Antimicrob Agents Chemother. 2015 Dec 28;60(3):1194-201. doi: 10.1128/AAC.02231-15. Antimicrob Agents Chemother. 2015. PMID: 26711766 Free PMC article. Review.
-
Combination antimicrobial therapy to manage resistance.Evol Med Public Health. 2023 Mar 30;11(1):185-186. doi: 10.1093/emph/eoad005. eCollection 2023. Evol Med Public Health. 2023. PMID: 37360836 Free PMC article. No abstract available.
-
The combination of rifampin plus moxifloxacin is synergistic for suppression of resistance but antagonistic for cell kill of Mycobacterium tuberculosis as determined in a hollow-fiber infection model.mBio. 2010 Aug 10;1(3):e00139-10. doi: 10.1128/mBio.00139-10. mBio. 2010. PMID: 20802826 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous